Eyenovia Pipeline
Product Development at Eyenovia
With our transformative microdosing technology, we are developing a treatment for progressive myopia. This condition often leads to high myopia which can increase the risk of cataract, glaucoma, retinal detachment, and myopic macular degeneration, and cause irreversible vision loss1,2,3,4,5,6. Eyenovia is a rapidly emerging clinical stage, ophthalmic biopharmaceutical company that is transforming modern eyecare primarily in areas of high unmet need including progressive myopia, presbyopia, and pupil dilation. We believe our technology enables these first-in-class microdosed therapies to improve the overall patient experience as they are designed to reduce ocular and systemic toxicity, improve the risk-benefit profile of drugs and lower the risk of drug contamination.
1. Vongphanit, J., Mitchell, P., & Wang, J. J. (2002). Prevalence and progression of myopic retinopathy in an older population. Ophthalmology, 109(4), 704-711.
2. Ogawa, A., & Tanaka, M. (1988). The relationship between refractive errors and retinal detachment–analysis of 1,166 retinal detachment cases. Japanese journal of ophthalmology, 32(3), 310-315.
3. Lim, R., Mitchell, P., & Cumming, R. G. (1999). Refractive associations with cataract: the blue mountains eye study. Investigative ophthalmology & visual science, 40(12), 3021-3026.
4. Mitchell, P., Houriha4. n, F., Sandbach, J., & Wang, J. J. (1999). The relationship between glaucoma and myopia: the Blue Mountains Eye Study. Ophthalmology, 106(10), 2010-2015.
5. Theophanous, Christos et al. “Myopia prevalence and risk factors in children.” Clinical ophthalmology (Auckland, N.Z.) vol. 12 1581-1587. 29 Aug. 2018, doi:10.2147/OPTH.S164641.
6. Chia, Audrey, et al. “Five-Year Clinical Trial on Atropine for the Treatment of Myopia” Ophthalmology, vol. 123, no. 2, 2016, pp. 391–399., doi:10.1016/j.ophtha.2015.07.004.
MydCombi (Mydriasis)
MydCombi is our proprietary, first-in-class fixed combination microdose formulation of phenylephrine and tropicamide for mydriasis (pupil dilation). Eyenovia’s delivery technology is intended to make this part of the exam both faster and more comfortable for patients, reducing the number of doses for dilation and potentially minimizing dose-related side effects. This anesthetic free dilation is without overflow, so there is no need to wipe away excess drug that may fall out of the eye. MydCombi is delivered rapidly in a horizontal mist by the Optejet which by design has a shutter that opens and closes during dispensing to minimize risk of cross-contamination.
MicroLine (Presbyopia)
On the presbyopia management horizon is pharmacologic treatment. Miotic agents such as Pilocarpine are being studied to improve near vision blur from presbyopia. Pilocarpine has been demonstrated to constrict the pupil of the eye and create a “pinhole” effect that increases the depth of field. Similar to a pinhole camera, near and intermediate objects are brought into an expanded depth of focus. This pinhole approach has been successfully used with contact lenses and surgery. Now with a less invasive approach using MicroLine, Eyenovia looks towards an improved risk/benefit drug profile while providing on demand near vision with its microdosed drug.
MicroPine (Myopia)
MicroPine™ is our proprietary microdose formulation of low dose atropine and product candidate for the prevention of progressive myopia (nearsightedness) in children. Moderate-to-severe myopia is associated with a lengthening of the eye. This can lead to significant stretching of tissues in the back-of-the eye causing permanent visual problems associated with retinal detachment, choroidal & retinal atrophy, and choroidal neovascularization1,2,3,4,5,6. In the US alone, there are approximately 25 million children with myopia, with up to 3 million considered to be at risk for high myopia and many times more that number in Asia5,7. Pathologic myopia is an important cause of vision loss worldwide, affecting up to 3% of the population.
1. Vongphanit, J., Mitchell, P., & Wang, J. J. (2002). Prevalence and progression of myopic retinopathy in an older population. Ophthalmology, 109(4), 704-711.
2. Ogawa, A., & Tanaka, M. (1988). The relationship between refractive errors and retinal detachment–analysis of 1,166 retinal detachment cases. Japanese journal of ophthalmology, 32(3), 310-315.
3. Lim, R., Mitchell, P., & Cumming, R. G. (1999). Refractive associations with cataract: the blue mountains eye study. Investigative ophthalmology & visual science, 40(12), 3021-3026.
4. Mitchell, P., Houriha4. n, F., Sandbach, J., & Wang, J. J. (1999). The relationship between glaucoma and myopia: the Blue Mountains Eye Study. Ophthalmology, 106(10), 2010-2015.
5. Theophanous, Christos et al. “Myopia prevalence and risk factors in children.” Clinical ophthalmology (Auckland, N.Z.) vol. 12 1581-1587. 29 Aug. 2018, doi:10.2147/OPTH.S164641.
6. Chia, Audrey, et al. “Five-Year Clinical Trial on Atropine for the Treatment of Myopia” Ophthalmology, vol. 123, no. 2, 2016, pp. 391–399., doi:10.1016/j.ophtha.2015.07.004.
7. U.S. Census Bureau, Current Population Survey, Annual Social and Economic Supplement, 2019.